Inside the research
Danaher Corporation
DHR Research profile · latest available data
Price overview
$224.49
▲ +0.72 (+0.3%)
| 52w hi | $241.04 |
|---|---|
| 52w lo | $161.57 |
| Vol | 4.42M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.21
| Short | +0.12 |
|---|---|
| Medium | +0.29 |
| Long | +0.26 |
computed 2026-09-27
Key fundamentals
Danaher Corporation
Healthcare · Diagnostics & Research
| Market cap | $157.81B |
|---|---|
| Enterprise value | $181.33B |
| Trailing P/E | 40.02x |
| Forward P/E | 24.14x |
| EV / EBITDA | 22.59x |
| P / S (ttm) | 6.29x |
| Profit margin | 15.9% |
| Return on equity | 7.6% |
| Revenue growth | +5.5% |
| Earnings growth | +59.7% |
| Debt / equity | 52.97 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.24 | |
| Sector | +0.08 | |
| Technical | +0.02 | |
| Earnings | +0.00 | |
| Sentiment | +0.14 |
macro × 1.00 · 2026-09-27
Business overview
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Risk Metrics
| Beta vs SPX | 0.79 |
|---|---|
| Corr SPX | 0.41 |
| Annual vol | 31.2% |
| Annual ret | -4.8% |
| Sharpe | -0.16 |
| Max DD | -41.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $250.14 |
|---|---|
| High / Low | $310.00 / $205.00 |
| Median | $247.50 |
| Analysts | 22 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 19 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-23 | Morgan Stanley | → Overweight |
| 2026-04-22 | Wells Fargo | → Equal-Weight |
| 2026-04-22 | UBS | → Buy |
| 2026-04-22 | Guggenheim | → Buy |
| 2026-04-22 | Baird | → Outperform |
| 2026-04-17 | Baird | → Outperform |
Officers & Board
| Founder | Mitchell Rales current |
|---|---|
| Manager | Steven Rales current |
| Founder | Steven Rales current |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-03 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-07-21 | Earnings Release, Exhibits | read |
| 2026-06-03 | Material Obligation, Other Material Event | read |
| 2026-05-07 | Officer / Director Change, Shareholder Vote… | read |
| 2026-04-29 | Material Agreement, Other Material Event… | read |
| 2026-04-21 | Earnings Release, Exhibits | read |
| 2026-04-17 | Material Agreement, Material Obligation… | read |
| 2026-02-17 | Other Material Event, Exhibits | read |
| 2026-02-10 | Officer / Director Change, Exhibits | read |
| 2026-01-28 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Exhibits | read |
| 2025-11-06 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Gutierrez-Ramos Jose-Carlos | SVP, Chief Science Office | Grant | 13.48K | — |
| 2026-08-04 | Riley Christopher Paul | Executive Vice President | Grant | 41.07K | — |
| 2026-08-04 | Milosevich Gregory M | Executive Vice President | Grant | 15.40K | — |
| 2026-05-01 | SPOON ALAN G | Option exercise | 3.30K | $237.06K | |
| 2026-05-01 | SPOON ALAN G | Sell | 1.36K | $237.21K | |
| 2026-03-01 | Milosevich Gregory M | Executive Vice President | Withheld for tax | 118 | $24.86K |
| 2026-03-01 | Bouda Christopher | VP, Chief Accounting Offi | Grant | 1.25K | — |
| 2026-03-01 | Bouda Christopher | VP, Chief Accounting Offi | Withheld for tax | 170 | $35.81K |
| 2026-03-01 | Gutierrez-Ramos Jose-Carlos | SVP, Chief Science Office | Grant | 6.65K | — |
| 2026-03-01 | Gutierrez-Ramos Jose-Carlos | SVP, Chief Science Office | Withheld for tax | 284 | $59.82K |
Flow & Concentration
| Insider 180d net | -$237.21K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.4% |
| HHI | 3,684 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Vanguard Group Inc | $13.96B | 60.98M |
| State Street Corp | $6.35B | 27.68M |
| Fidelity / FMR LLC | $4.47B | 19.51M |
| Citadel Advisors | $625.03M | 2.73M |
| Millennium Management | $531.72M | 2.32M |
| AQR Capital Management | $415.55M | 1.82M |
| Bridgewater Associates | $7.26M | 31.72K |
| T. Rowe Price Group | $3.66M | 15.97M |
As of 2025-12-31
Dividends
| Yield (TTM) | 0.32% |
|---|---|
| $ / share (TTM) | $0.72 |
| 5y CAGR | +14.9% |
Annual dividend per share
| 2021 | $0.74 |
|---|---|
| 2022 | $0.89 |
| 2023 | $0.99 |
| 2024 | $1.08 |
| 2025 | $1.28 |
| 2026 | $0.40 |
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $146.27M | Department of Veterans Affairs | COVID 19 FLU TEST KITS AND SWABS |
| $74.98M | Department of Health and Human Services | OTA - PANDEMIC PREPAREDNESS AND RESPONSE: ESTABLISHING A PLATFORM FOR DIAGNOSIS |
| $72.10M | Department of Health and Human Services | OTHER TRANSACTION AGREEMENT: CAPACITY EXPANSION FOR COVID-19 RESPONSE AND IN SUP |
| $59.69M | Department of Defense | COVID-19 DHHS INDUSTRIAL BASE EXPANSION FOR TEST KITS. |
| $37.83M | Department of Defense | COVID TESTS, DIAGNOSTIC SYSTEMS AND SERVICE AGREEMENTS. |
| $13.39M | Department of Health and Human Services | AB SCIEX SERVICE & MAINTENANCE AGREEMENT SUPPORT |
| $13.01M | Department of Health and Human Services | IGF::OT::IGFC103555 - (WATER TREATMENT)-REQUIREMENTS OUTLINED IN SOWLEO ANGELO G |
| $9.33M | Department of Veterans Affairs | MOLECULAR DIAGNOSTIC TESTS FOR SARS-COV-2 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $23.88B | +4.0% | |
| Gross profit | $14.03B | +16.1% | |
| Operating income | $4.86B | +6.6% | |
| Net income | $3.61B | +6.5% | |
| Cash from ops | $6.69B | +8.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $223.37 | $224.90 | $221.60 | $224.49 | 4.42M |
| Sep 24 | $220.50 | $226.65 | $219.00 | $223.77 | 6.20M |
| Sep 23 | $221.27 | $223.42 | $219.92 | $221.56 | 3.40M |
| Sep 22 | $215.10 | $222.42 | $214.28 | $221.09 | 4.63M |
| Sep 21 | $212.03 | $216.19 | $209.60 | $215.84 | 5.16M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →